Clinical trial
The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart…
NCT00283335 · VA Office of Research and Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00283335 |
|---|---|
| Title | The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol |
| Official title | CSP #363 - The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol |
| Acronym | HIT |
| Lead sponsor | VA Office of Research and Development, U.S. Fed |
| Collaborators | Parke-Davis Industry Fournier Labs |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Coronary Heart Disease |
| Intervention type | Drug, Other |
| Interventions | gemfibrozil, Placebo |
| Enrollment | 2,531 |
| Start date | Jun 1, 1991 |
| Primary completion | Sep 1, 1998 |
| Completion | Aug 1, 1999 |
| First posted | Jan 27, 2006 |
| Last update posted | Oct 21, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: